Novo Nordisk bulks up in rare diseases with $1.2bn Prothena deal
pharmaphorum
JULY 13, 2021
The Danish drugmaker is paying $100 million upfront for rights to antibody drug PRX004, which is heading for phase 2 trials in cardiomyopathy associated with ATTR amyloidosis, a life-threatening disease affecting the heart and nervous system. All told, the deal could be worth up to $1.2
98 
Let's personalize your content